benmelstobart-Anlotinib-Chemo

Phase 2Small molecule

JJiangsu Cancer Institute & Hospital

benmelstobart-Anlotinib-Chemo is one of 4 small molecule programs targeting Benmelstobart. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BenmelstobartNot yet recruiting

BenmelstobartPhase 2

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Benmelstobart

#DrugCompanyPhaseTrials

Opzelura

DDizal Pharmaceuticals

Phase 2

1 2

Benmelstobart

SSun Yat-sen University

Phase 2

1 3

Anlotinib Plus Sintilimab

SSun Yat-sen University

Phase 2

1 4

benmelstobart-Anlotinib-Chemo

JJiangsu Cancer Institute & Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Benmelstobart

NCT06848439

Clinical

Trials by Indication[1]

Benmelstobart1 trial

Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer

Not yet recruiting·JJiangsu Cancer Institute & Hospital·Phase 2·NCT06848439·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for benmelstobart-Anlotinib-Chemo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — benmelstobart-Anlotinib-Chemo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for benmelstobart-Anlotinib-Chemo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Cancer Institute & Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJiangsu Cancer Institute & Hospital

benmelstobart-Anlotinib-Chemo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Benmelstobart1 trial

References

Drug Info

Quick Facts

Related News